The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Immunotherapy in ovarian cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“The first published data supporting checkpoint inhibitors as a potentially valuable therapeutic approach in ovarian cancer were observed in trials of the anti-PD-1 antibody nivolumab and the anti PD-L1 antibody BMS-93655 [18].”
BackgroundSelf-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“tumor in a single biopsy [37, 38], it is evident that the vast majority of neoantigens occur within exonic sequence and do not lead to the formation of neoantigens that are recognized by autologous T cells [38, 39].”
BackgroundPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Indirect support for this approach comes from studies demonstrating that (i) infusion of autologous ex vivo expanded TILs can induce objective clinical responses in metastatic melanoma [30], and (ii) the relationship between pre-therapy CD8þ T-cell infiltrates and response to checkpoint blockade in melanoma [31].”
ResultCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,263
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Self-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Global estimates of cancer prevalence for 27 sites in the adult population in 2008
Bray, F., Ren, J., Masuyer, E., & Ferlay, J. (2013) · International Journal of Cancer · doi:10.1002/ijc.27711 · Cited by 1,891
Cancer/testis antigens, gametogenesis and cancer
Simpson, A. J. G., Caballero, O. L., Jungbluth, A., Chen, Y.-T., & Old, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1669 · Cited by 1,582
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,180
Fallarino, F., Grohmann, U., You, S., McGrath, B. C., Cavener, D. R., Vacca, C., Orabona, C., Bianchi, R., Belladonna, M. L., Volpi, C., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6752 · Cited by 1,047
Bonifaz, L. C., Bonnyay, D. P., Charalambous, A., Darguste, D. I., Fujii, S.-I., Soares, H., Brimnes, M. K., Moltedo, B., Moran, T. M., & Steinman, R. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20032220 · Cited by 921
Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003345107 · Cited by 859
Self-citationExploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 810
Linnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3773 · Cited by 679
Pegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 678
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
Hwang, W.-T., Adams, S. F., Tahirovic, E., Hagemann, I. S., & Coukos, G. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.039 · Cited by 661
Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.36 · Cited by 613
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S., & Brentjens, R. J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994446 · Cited by 418
Lu, Y.-C., Yao, X., Crystal, J. S., Li, Y. F., El-Gamil, M., Gross, C., Davis, L., Dudley, M. E., Yang, J. C., Samuels, Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0433 · Cited by 401
Huang, R.-Y., Francois, A., McGray, A. R., Miliotto, A., & Odunsi, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1249561 · Cited by 388
Self-citationDuan, F., Duitama, J., Al Seesi, S., Ayres, C. M., Corcelli, S. A., Pawashe, A. P., Blanchard, T., McMahon, D., Sidney, J., Sette, A., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20141308 · Cited by 378
Huang, R.-Y., Eppolito, C., Lele, S., Shrikant, P., Matsuzaki, J., & Odunsi, K. (2015) · Oncotarget · doi:10.18632/oncotarget.4751 · Cited by 308
Self-citationKoneru, M., O’Cearbhaill, R., Pendharkar, S., Spriggs, D. R., & Brentjens, R. J. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0460-x · Cited by 302
Odunsi, K. O., Jungbluth, A. A., Stockert, E., Qian, F., Gnjatic, S., Tammela, J., Intengan, M., Beck, A. F., Keitz, B. T., Santiago, D., et al. (2003) · PubMed · Cited by 275
Self-citationOdunsi, K., Qian, F., Matsuzaki, J., Mhawech-Fauceglia, P., Andrews, C., Hoffman, E. W., Pan, L., Ritter, G., Villella, J., Thomas, B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703342104 · Cited by 270
Self-citationBozzacco, L., Trumpfheller, C., Siegal, F. P., Mehandru, S., Markowitz, M., Carrington, M., Nussenzweig, M. C., Piperno, A. G., & Steinman, R. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610383104 · Cited by 247
Dudley, M. E., Gross, C. A., Somerville, R. P. T., Hong, Y., Schaub, N. P., Rosati, S. F., White, D. E., Nathan, D., Restifo, N. P., Steinberg, S. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.6441 · Cited by 235
Odunsi, K., Matsuzaki, J., Karbach, J., Neumann, A., Mhawech-Fauceglia, P., Miller, A., Beck, A., Morrison, C. D., Ritter, G., Godoy, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117208109 · Cited by 200
Self-citationEpigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
Odunsi, K., Matsuzaki, J., James, S. R., Mhawech-Fauceglia, P., Tsuji, T., Miller, A., Zhang, W., Akers, S. N., Griffiths, E. A., Miliotto, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0126 · Cited by 193
Self-citationCancer/testis (CT) antigens - a new link between gametogenesis and cancer.
Old, L. J. (2001) · PubMed · Cited by 190
Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation
Munn, D. H. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.002 · Cited by 176
Nishikawa, H., Jäger, E., Ritter, G., Old, L. J., & Gnjatic, S. (2005) · Blood · doi:10.1182/blood-2005-02-0607 · Cited by 173
Wick, D. A., Webb, J. R., Nielsen, J. S., Martin, S. D., Kroeger, D. R., Milne, K., Castellarin, M. L., Twumasi‐Boateng, K., Watson, P. H., Holt, R. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2147 · Cited by 167
Pegram, H. J., Purdon, T. J., van Leeuwen, D. G., Curran, K. J., Giralt, S., Barker, J. N., & Brentjens, R. J. (2014) · Leukemia · doi:10.1038/leu.2014.215 · Cited by 161
Varga, A., Piha-Paul, S. A., Ott, P. A., Mehnert, J. M., Berton-Rigaud, D., Johnson, E. A., Cheng, J. D., Yuan, S., Rubin, E. H., & Matei, D. E. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5510 · Cited by 158
Qian, F., Villella, J., Wallace, P. K., Mhawech-Fauceglia, P. Y., Tario, J. D., Andrews, C., Matsuzaki, J., Valmori, D., Ayyoub, M., Frederick, P. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2106 · Cited by 157
Self-citationDevelopment of CAR T cells designed to improve antitumor efficacy and safety
Jaspers, J. E., & Brentjens, R. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.012 · Cited by 117
Disis, M. L., Patel, M. R., Pant, S., Infante, J. R., Lockhart, A. C., Kelly, K. L., Beck, J. T., Gordon, M. S., Weiss, G. J., Ejadi, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5509 · Cited by 111
Minagawa, K., Jamil, M. O., Al‐Obaidi, M., Pereboeva, L., Salzman, D. E., Erba, H. P., Lamb, L. S., Bhatia, R., Mineishi, S., & Stasi, A. D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166891 · Cited by 84
Tsuji, T., Sabbatini, P. J., Jungbluth, A. A., Ritter, E., Pan, L. S., Ritter, G., Ferran, L. J., Spriggs, D. R., Salazar, A. Μ., & Gnjatic, S. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0089 · Cited by 77
NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer
Szender, J. B., Papanicolau‐Sengos, A., Eng, K. H., Miliotto, A. J., Lugade, A. A., Gnjatic, S., Matsuzaki, J., Morrison, C. D., & Odunsi, K. O. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.03.509 · Cited by 75
Self-citationQian, F., Liao, J., Villella, J., Edwards, R. P., Kaliński, P., Lele, S., Shrikant, P. A., & Odunsi, K. O. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1265-x · Cited by 70
Self-citationKhan, A. N. H., Kolomeyevskaya, N. V., Singel, K. L., Grimm, M. J., Moysich, K. B., Daudi, S., Grzankowski, K. S., Lele, S. B., Ylagan, L. R., Webster, G., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3597 · Cited by 50
Self-citationGschweng, E. H., McCracken, M. N., Kaufman, M. L., Ho, M., Hollis, R. P., Wang, X., Saini, N., Koya, R. C., Chodon, T., Ribas, A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0376 · Cited by 40
Resetca, D., Neschadim, A., & Medin, J. A. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000134 · Cited by 10
Minagawa, K., Jamil, M. O., Al‐Obaidi, M., Pereboeva, L., Salzman, D. E., Erba, H. P., Lamb, L. S., Bhatia, R., Mineishi, S., & Stasi, A. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172640 · Cited by 3
Cited by
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
Zamarin, D., Burger, R. A., Sill, M. W., Powell, D. J., Lankes, H. A., Feldman, M. D., Zivanovic, O., Gunderson, C., Ko, E., Mathews, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02059 · Cited by 345
Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
Yang, C., Xia, B.-R., Zhang, Z.-C., Zhang, Y.-J., Lou, G., & Jin, W.-L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577869 · Cited by 350
Zheng, X., Wang, X., Cheng, X., Liu, Z., Yin, Y., Li, X., Huang, Z., Wang, Z., Guo, W., Ginhoux, F., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00599-8 · Cited by 172
Cai, M., Yao, Y., Yin, D., Zhu, R., Fu, T., Kong, J., Wang, K., Liu, J., Yao, A., Ruan, Y., et al. (2023) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2023.04.126 · Cited by 45
Metadata
- Authors
- Odunsi, K.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 28
- Issue
- suppl_8
- Pages
- viii1-viii7
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2773771998
- Cited by
- 384
- References
- 54
- FWCI
- 23.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.